Data Year:

For its 2024 fiscal year, GERON CORP, listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2024
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
John A. Scarlett M.D.
Former Chairman of the Board, President and Chief Executive Officer
Total Compensation $6,125,238 View details Pay Rank By Title In Biotechnology industry #219 View more
Andrew J. Grethlein Ph.D.
Executive Vice President, Chief Operating Officer
Total Compensation $2,813,956 View details Pay Rank By Title In Biotechnology industry #57 View more
Michelle J. Robertson
Executive Vice President, Finance, Chief Financial Officer and Treasurer
Total Compensation $2,147,216 View details Pay Rank By Title In Biotechnology industry #224 View more
Joseph Eid M.D.
Executive Vice President, Research & Development
Total Compensation $7,206,598 View details Pay Rank By Title In Biotechnology industry #22 View more
James Ziegler
Executive Vice President, Chief Commercial Officer
Total Compensation $5,406,965 View details Pay Rank By Title In Biotechnology industry #38 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at GERON CORP as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. GERON CORP income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. GERON CORP annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
John A. Scarlett M.D.
Former Chairman of the Board, President and Chief Executive Officer
Total Cash $1,469,200 Equity $4,591,200 Other $64,838 $6,125,238
Andrew J. Grethlein Ph.D.
Executive Vice President, Chief Operating Officer
Total Cash $964,500 Equity $1,836,480 Other $12,976 $2,813,956
Michelle J. Robertson
Executive Vice President, Finance, Chief Financial Officer and Treasurer
Total Cash $832,800 Equity $1,300,840 Other $13,576 $2,147,216
Joseph Eid M.D.
Executive Vice President, Research & Development
Total Cash $293,750 Equity $6,902,500 Other $10,348 $7,206,598
James Ziegler
Executive Vice President, Chief Commercial Officer
Total Cash $251,521 Equity $5,154,400 Other $1,044 $5,406,965
For its 2024 fiscal year, GERON CORP, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
John A. Scarlett M.D. CEO Pay $6,125,238 Median Employee Pay $398,232 CEO Pay Ratio 15:1
For its 2024 fiscal year, GERON CORP, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Dawn Bir Total Cash $583,314
Elizabeth O'Farrell Total Cash $630,749
Gaurav Aggarwal, M.D. Total Cash $589,843
John McDonald Total Cash $588,249
Robert Spiegel Total Cash $583,321
Susan Molineaux Total Cash $582,471
V. Bryan Lawlis Total Cash $586,656
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.